Navigation Links
Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Date:12/2/2008

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the incidence of non-steroidal anti-inflammatory drug (NSAID)-induced upper gastrointestinal (gastric and/or duodenal) ulcers in patients with mild-to-moderate pain when compared to ibuprofen alone.

NSAIDs such as ibuprofen are among the most widely used drugs in the world. However, NSAIDs are associated with a range of adverse side effects, which primarily affect the gastrointestinal (GI) tract. Up to 30 percent of patients taking NSAIDs experience gastrointestinal ulcers and a greater percent suffer from upper GI symptoms (i.e., dyspepsia, heartburn).

"NSAIDs, while highly effective in treating pain and inflammation, often lead to serious safety concerns, including significant gastrointestinal damage," said Timothy P. Walbert, president and chief executive officer, Horizon Therapeutics. "We are committed to bringing this much needed treatment to physicians and patients as quickly as possible and plan on submitting these strong HZT 501 Phase 3 results to U.S. and European regulatory authorities in 2009."

REDUCE-1 and REDUCE-2 Trial Design and Results

The Registration Endoscopic Study to Determine Ulcer Formation of HZT 501 Compared to Ibuprofen: Efficacy and Safety Study (REDUCE 1 and REDUCE 2) were two randomized, double-blind, controlled trials that enrolled more than 1,500 patients in the United States. The primary efficacy objective of REDUCE-1 was to evaluate HZT 501 in reducing the proportion of patients who develop endoscopically diagnosed gastric ulcers during the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The primary objective of REDUCE-2 was to evaluate HZT 501 in reducing the proportion of patients who develop endoscopically diagnosed gastric and/or duodenal ulcers during the 24-week treatment period, as compared to ibuprofen, in patients at risk for NSAID-induced ulcers. The trials were conducted via a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA).

Patients, who had mild-to-moderate pain, including those with osteoarthritis, were randomly assigned, in approximately a 2:1 ratio, to receive HZT 501 (800 mg ibuprofen and 26.6 mg famotidine) or ibuprofen (800 mg) alone orally three times daily for a 24- week treatment period or until patients developed either an endoscopically diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Patients received endoscopies at baseline and weeks 8, 16 and 24.

In REDUCE-1, 24-week treatment with HZT 501 resulted in a statistically significant reduction in gastric ulcers versus treatment with ibuprofen alone. In REDUCE-2, 24-week treatment with HZT 501 resulted in a statistically significant reduction in gastric and/or duodenal ulcers versus treatment with ibuprofen alone.

Treatment with both HZT-501 and ibuprofen alone were well tolerated in the studies. The majority were mild to moderate in severity. There were no significant differences between the two treatment groups adverse event or serious adverse event profiles.

"NSAIDs can cause significant gastrointestinal damage, including ulcers of the stomach and duodenum" said Loren Laine, MD, professor of medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California. "These results indicate that HZT-501 can reduce the risk of ulcers, potentially improving the GI safety for patients treated with NSAIDs."


'/>"/>

Contact: Geoff Curtis
gcurtis@wcpglobal.com
312-646-6298
WeissComm Partners
Source:Eurekalert

Related medicine news :

1. Push-Ups: Its Horizontal Jogging
2. United Healthcare Workers Win New Contract with Horizon West
3. Bright Horizons Founders Receive Corporate Partner Award from Ackerman Institute
4. Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best
5. U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes
6. PFCD Experts Cite Health Care as Next Financial Casualty on Horizon
7. NJHA: Public Deserves Full Disclosure of Horizon Conversion Plan
8. Indonesias Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
9. NJHA Raises Questions Regarding Horizons Proposal to Convert to For-Profit Health Insurer
10. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
11. RxPop.com Wins 7th Annual Horizon Interactive Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... Technique, technique, technique ... injury when either lifting weights for strength training and exercise or simply lifting heavy ... . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting anything ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a leading ... that its iClinic V12.2 solution has achieved approval from National Center for Quality ... 2017 standards which emphasize team-based care with a significant focus on the care ...
(Date:5/23/2017)... ... , ... Allegheny Health Network and the Alexis Joy D’Achille ... Behavioral Health at West Penn Hospital , a unique facility that will offer ... depression. Construction of the Center is underway with a scheduled opening in the ...
(Date:5/23/2017)... ... 2017 , ... Cambridge, MA, May 23, 2017—Total costs per ... a Workers Compensation Research Institute (WCRI) study, a contrast from the increases of ... Benchmarks, 17th Edition looks at indemnity and medical payments for workers’ compensation ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i ... 2017 Best in KLAS category winner, has named Daniel P. Bullington as chief ... enhance its technology platform and product offerings,” says Justin Neece, president. “Daniel is ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
Breaking Medicine Technology: